<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Community-acquired pneumonia in children: Outpatient treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Community-acquired pneumonia in children: Outpatient treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Community-acquired pneumonia in children: Outpatient treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J Barson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Community-acquired pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community, as distinguished from hospital-acquired (nosocomial) pneumonia. CAP is a common and potentially serious illness with considerable morbidity.</p><p>The Pediatric Infectious Diseases Society/Infectious Diseases Society of America and the British Thoracic Society have developed clinical practice guidelines for the evaluation and treatment of CAP in children [<a href="#rid1">1,2</a>].</p><p>The outpatient treatment of CAP in infants and children in resource-abundant settings will be reviewed here. Neonatal pneumonia, coronavirus disease 2019-related pneumonia, and the etiology, clinical features, diagnosis, and inpatient treatment of pneumonia in children are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5004.html" rel="external">"Neonatal pneumonia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127488.html" rel="external">"COVID-19: Clinical manifestations and diagnosis in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5979.html" rel="external">"Pneumonia in children: Epidemiology, pathogenesis, and etiology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">"Pneumonia in children: Inpatient treatment"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">INDICATIONS FOR HOSPITALIZATION</span><span class="headingEndMark"> — </span>The decision to hospitalize a child with CAP is individualized based upon age, underlying medical problems, and clinical factors including severity of illness (<a class="graphic graphic_table graphicRef72015" href="/z/d/graphic/72015.html" rel="external">table 1</a>) [<a href="#rid1">1-3</a>]. Hospitalization generally is warranted for infants younger than three to six months of age, unless a viral etiology or <em>Chlamydia trachomatis</em> is suspected and they are normoxemic and relatively asymptomatic. Hospitalization is also warranted for a child of any age whose caregivers cannot provide appropriate care and assure compliance with the therapeutic regimen. Additional indications for hospitalization include [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoxemia (oxygen saturation &lt;90 percent in room air at sea level)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dehydration, or inability to maintain hydration orally; inability to feed in an infant</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate to severe respiratory distress: Respiratory rate &gt;70 breaths per minute for infants &lt;12 months of age and &gt;50 breaths per minute for older children; difficulty breathing (grunting, nasal flaring, retractions); apnea</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Toxic appearance (more common in bacterial pneumonia and may suggest a more severe course) [<a href="#rid4">4</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Underlying conditions that may predispose to a more serious course of pneumonia (eg, cardiopulmonary disease, genetic syndromes, neurocognitive disorders), may be worsened by pneumonia, even viral pneumonia (eg, metabolic disorder) or may adversely affect response to treatment (eg, immunocompromised host)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complications (eg, effusion/empyema, necrotizing process, abscess) (see  <a class="medical medical_review" href="/z/d/html/6344.html" rel="external">"Epidemiology, clinical presentation, and evaluation of parapneumonic effusion and empyema in children"</a> and  <a class="medical medical_review" href="/z/d/html/6345.html" rel="external">"Management and prognosis of parapneumonic effusion and empyema in children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suspicion or confirmation that CAP is due to a pathogen with increased virulence, such as <em>Staphylococcus aureus</em> or group A <em>Streptococcus</em></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Failure of outpatient therapy (worsening or no response in 48 to 72 hours) (see <a class="local">'Treatment failure'</a> below)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">EMPIRIC THERAPY</span></p><p class="headingAnchor" id="H4"><span class="h2">Factors influencing choice of regimen</span><span class="headingEndMark"> — </span>Children with CAP who are treated in the outpatient setting typically are treated empirically; tests to identify a bacterial etiology are not recommended for most children who are well enough to be treated in the outpatient setting [<a href="#rid1">1,2</a>]. Decisions regarding empiric therapy are complicated by the substantial overlap in the clinical presentation of bacterial and nonbacterial pneumonias [<a href="#rid2">2,5,6</a>].</p><p>Treatment decisions are usually based upon algorithms that include patient age (<a class="graphic graphic_table graphicRef80561" href="/z/d/graphic/80561.html" rel="external">table 2</a>), epidemiologic and clinical information (<a class="graphic graphic_table graphicRef52021" href="/z/d/graphic/52021.html" rel="external">table 3</a>), and diagnostic laboratory and imaging studies (if such studies are obtained) [<a href="#rid4">4,7</a>]. Consultation with a specialist in infectious diseases may be helpful in children with medication allergies or comorbid conditions. (See  <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5979.html" rel="external">"Pneumonia in children: Epidemiology, pathogenesis, and etiology", section on 'Etiologic agents'</a>.)</p><p>There are few randomized controlled trials to guide the choice of empiric antibiotics in children with CAP. Factors that must be considered include the spectrum of likely pathogens, antimicrobial susceptibility, simplicity, tolerability, palatability, safety, and cost [<a href="#rid8">8</a>]. The recommendations of most guidelines are based upon observations regarding the susceptibility of the most likely pathogen or pathogens, rather than on evidence of the superiority of one antibiotic over another [<a href="#rid1">1,2</a>]. The clinical response to the most commonly used antimicrobials appears to be similar, regardless of etiology [<a href="#rid9">9-11</a>]. The response within the first 48 to 72 hours of empiric therapy (or lack of therapy if a viral etiology is most likely) helps to determine whether additional evaluation or changes in therapy are necessary. (See <a class="local">'Monitoring response'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h2">Children &lt;5 years</span></p><p class="headingAnchor" id="H6"><span class="h3">Neonates</span><span class="headingEndMark"> — </span>The treatment of neonatal pneumonia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5004.html" rel="external">"Neonatal pneumonia"</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">One to six months</span><span class="headingEndMark"> — </span>Infants younger than three to six months of age with suspected bacterial CAP or who are hypoxemic (oxygen saturation &lt;90 percent in room air at sea level) should be admitted to the hospital for empiric therapy. (See  <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">"Pneumonia in children: Inpatient treatment", section on 'Empiric therapy'</a>.)</p><p>In afebrile infants one to four months of age with CAP, the most likely bacterial pathogen is <em>C. trachomatis</em> (ie, "afebrile pneumonia of infancy") [<a href="#rid4">4,12</a>]. Infants who are thought to have afebrile pneumonia of infancy can be treated in the outpatient setting if they are not hypoxemic and remain afebrile [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/4993.html" rel="external">"Chlamydia trachomatis infections in the newborn", section on 'Treatment'</a>.)</p><p><em>Bordetella pertussis</em> is a less common, but more severe, cause of pneumonia in young infants; fever may or may not be present. Like <em>C. trachomatis</em>, <em>B. pertussis</em> is susceptible to the macrolides [<a href="#rid4">4</a>]. However, young infants who are thought to have <em>B. pertussis</em>-associated pneumonia should be admitted to the hospital because they are at risk for complications (eg, hypoxia, apnea, pulmonary hypertension, etc). (See  <a class="medical medical_review" href="/z/d/html/5995.html" rel="external">"Pertussis infection in infants and children: Clinical features and diagnosis", section on 'Infants younger than 12 months'</a> and  <a class="medical medical_review" href="/z/d/html/5997.html" rel="external">"Pertussis infection in infants and children: Treatment and prevention", section on 'Hospitalization'</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Six months to five years</span></p><p class="headingAnchor" id="H34408226"><span class="h4">Suspected viral etiology</span><span class="headingEndMark"> — </span>Viral etiologies predominate during early childhood. Viral pneumonia (suggested by gradual onset, preceding upper respiratory tract symptoms, diffuse findings on auscultation, lack of toxic appearance (<a class="graphic graphic_table graphicRef52021" href="/z/d/graphic/52021.html" rel="external">table 3</a>)) should <strong>not</strong> be treated with antibiotics. (See  <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Clues to etiology'</a> and  <a class="medical medical_review" href="/z/d/html/5979.html" rel="external">"Pneumonia in children: Epidemiology, pathogenesis, and etiology", section on 'Etiologic agents'</a>.)</p><p>Infants and young children with known or suspected chronic disease (eg, cardiopulmonary disease, neuromuscular disease, etc) are at increased risk for severe or complicated viral lower respiratory tract infection (LRTI). If such children are not admitted to the hospital, they merit close monitoring in the outpatient setting.</p><p>Antiviral agents generally are not used for viral pneumonia in the outpatient setting, with the exception of antiviral therapy for influenza pneumonia and possibly for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia (eg, <a class="drug drug_pediatric" data-topicid="134696" href="/z/d/drug information/134696.html" rel="external">nirmatrelvir-ritonavir</a> for children ≥12 years of age who weigh ≥40 kg [via emergency use authorization]).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suspected influenza</strong> – In children with suspected influenza who are at increased risk of complications (<a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">table 4</a>), initiation of antiviral treatment is recommended as soon as possible; laboratory confirmation should not delay initiation of antiviral therapy. The diagnosis and treatment of influenza in children are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5973.html" rel="external">"Seasonal influenza in children: Clinical features and diagnosis", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">"Seasonal influenza in children: Management", section on 'Antiviral therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suspected SARS-CoV-2 pneumonia</strong> – SARS-CoV-2 pneumonia may be suspected in children with known exposure or circulation in the local community, school, or site of child care. The management of SARS-CoV-2 in children is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/128389.html" rel="external">"COVID-19: Management in children"</a>.)</p><p></p><p class="headingAnchor" id="H34408249"><span class="h4">Suspected bacterial etiology</span><span class="headingEndMark"> — </span><em>Streptococcus pneumoniae</em> is the most frequent cause of "typical" bacterial pneumonia in children of all ages [<a href="#rid1">1,2</a>]. Less frequent etiologies include <em>S. aureus, Streptococcus pyogenes</em> (group A <em>Streptococcus</em>), and the unusual typeable and nontypeable <em>Haemophilus influenzae</em> and <em>Moraxella catarrhalis</em>. Bacterial pneumonia in preschool children usually causes more severe infection, with abrupt onset and moderate to severe respiratory distress, which may require inpatient therapy. (See <a class="local">'Indications for hospitalization'</a> above and  <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">"Pneumonia in children: Inpatient treatment", section on 'Empiric therapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred regimen</strong> – For appropriately immunized, healthy children younger than five years who are thought to have bacterial CAP based upon clinical presentation, examination findings, and supportive radiographic or laboratory data if obtained (eg, lobar consolidation on radiograph, white blood cell count &gt;15,000/microL, C-reactive protein &gt;35 to 60 mg/L [3.5 to 6 mg/dL] (<a class="graphic graphic_table graphicRef52021" href="/z/d/graphic/52021.html" rel="external">table 3</a>)), but do not require inpatient therapy, <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> is usually considered the drug of choice [<a href="#rid1">1,2,13</a>]. We suggest high-dose amoxicillin (90 to 100 mg/kg per day divided into two or three doses; maximum dose 4 g/day) (<a class="graphic graphic_table graphicRef80561" href="/z/d/graphic/80561.html" rel="external">table 2</a>). High-dose <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> (90 mg/kg per day of the amoxicillin component divided into two or three doses) is an alternative for children aged six months to five years given the possibility of <em>H. influenzae</em> and <em>M. catarrhalis</em> in this age group.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">Amoxicillin</a> is preferred because it will be effective in the majority of episodes of bacterial CAP in this age group, is well tolerated, and is inexpensive [<a href="#rid1">1,2</a>]. Amoxicillin is more active in vitro than any of the oral cephalosporins against isolates of <em>S. pneumoniae</em>.</p><p></p><p class="bulletIndent1">The higher dose of <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> is suggested because of the concern for antibiotic-resistant <em>S. pneumoniae</em> isolated from patients with community-acquired respiratory tract infections [<a href="#rid14">14-16</a>], although there is some evidence that lower doses may be sufficient. In a 2 x 2 multicenter randomized trial, 591 young children (age ≥6 months with weight between 6 and 24 kg) discharged from the emergency department with a clinical diagnosis of CAP and treated with amoxicillin were assigned to a lower (35 to 50 mg/kg per day) or higher (70 to 90 mg/kg per day) dose administered twice per day for three or seven days [<a href="#rid17">17</a>]. None of the participants were colonized with penicillin-resistant pneumococci. The rates of antibiotic retreatment for respiratory infection within 28 days of randomization were similar in the lower and higher dose groups (11.7 versus 12.8 percent; difference -1.5 percent, 90% CI -6.0 to 3.0 percent).</p><p></p><p class="bulletIndent1">Although the prevalence of penicillin-resistant pneumococci initially decreased after universal infant immunization with the 7-valent pneumococcal conjugate vaccine (PCV7) and replacement of PCV7 with the <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">13-valent pneumococcal conjugate vaccine</a> (PCV13) in 2010 [<a href="#rid1">1,18</a>], surveillance since 2013 suggests increasing antibiotic nonsusceptibility among pneumococcal strains that are not included in PCV13 (eg, 11A, 35B, 35F) [<a href="#rid16">16</a>]. Continued surveillance is needed. In the United States, a 15-valent PCV (<a class="drug drug_pediatric" data-topicid="139114" href="/z/d/drug information/139114.html" rel="external">PCV15</a>) was licensed for people ≥6 weeks of age in 2022 and a 20-valent PCV (<a class="drug drug_pediatric" data-topicid="141485" href="/z/d/drug information/141485.html" rel="external">PCV20</a>) was licensed for people ≥18 years of age in 2021 (<a class="graphic graphic_table graphicRef77274" href="/z/d/graphic/77274.html" rel="external">table 5</a>) [<a href="#rid19">19,20</a>]. (See  <a class="medical medical_review" href="/z/d/html/7034.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to beta-lactam antibiotics"</a>.)</p><p></p><p class="bulletIndent1">Although there are prospective, comparative data supporting the efficacy of twice daily dosing of <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> for the treatment of acute otitis media [<a href="#rid21">21-23</a>], similar data are not available for documented pneumococcal pneumonia in children. Unless the etiologic agent is identified as a <em>S. pneumoniae</em> isolate with a minimum inhibitory concentration (MIC) of &lt;2 mcg/mL, dividing the total daily 90 to 100 mg/kg dose of amoxicillin into three doses may be warranted. Twice daily dosing for pneumonia due to a <em>S. pneumoniae</em> isolate with an MIC of 2 mcg/mL is predicted to achieve a clinical and microbiologic cure in only 65 percent of children, whereas the same total daily dose divided in three equal portions is predicted to achieve a cure in 90 percent [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative regimens</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>History of reaction to a penicillin</strong> – Regimens for children with a history of drug reaction to a penicillin depend upon the type of reaction (<a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions", section on 'Clinical history'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children with nonallergic reactions to a penicillin may be treated with <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a>.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For children with mild reactions to a penicillin and no features of an immunoglobulin (IgE)-mediated reaction, options include <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> or a third-generation cephalosporin [<a href="#rid1">1</a>]. The choice is individualized according to the drug allergy history and the ability to safely conduct an oral challenge if necessary [<a href="#rid25">25,26</a>]. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients", section on 'Management of mild reactions WITHOUT history of features of immediate allergy (minimal risk of immediate allergy)'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For children with IgE-mediated or serious delayed reactions to a penicillin, <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a>, <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">levofloxacin</a>, or <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">linezolid</a> may be used [<a href="#rid1">1,2</a>].</p><p></p><p class="bulletIndent2">Doses are provided in the table (<a class="graphic graphic_table graphicRef80561" href="/z/d/graphic/80561.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inability to tolerate oral therapy</strong> – For the infant or child who is suspected to have bacterial CAP and is unable to tolerate liquids at the time of presentation, a <strong>single</strong> initial dose of <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> (50 to 75 mg/kg) may be administered intramuscularly or intravenously before starting oral antibiotics [<a href="#rid27">27,28</a>]. Administration of intramuscular ceftriaxone to children with uncomplicated CAP who are able to tolerate liquids is expensive and provides no benefit over oral antibiotics.</p><p></p><p class="headingAnchor" id="H264608206"><span class="h4">Suspected atypical pneumonia</span><span class="headingEndMark"> — </span><em>Mycoplasma pneumoniae</em> and<em> Chlamydia pneumoniae</em> are less common than <em>S. pneumoniae</em> in children younger than five years with CAP [<a href="#rid5">5</a>]. However, they can occur in this age group and should be considered in children without a pneumonia-associated complication who fail to improve after 48 to 72 hours of empiric therapy for <em>S. pneumoniae</em> (eg, <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a>), at which time a macrolide could be added or substituted (<a class="graphic graphic_table graphicRef80561" href="/z/d/graphic/80561.html" rel="external">table 2</a>). (See <a class="local">'Treatment failure'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h2">Children ≥5 years</span></p><p class="headingAnchor" id="H289604"><span class="h3">Suspected typical or atypical bacterial etiology</span><span class="headingEndMark"> — </span><em>S. pneumoniae</em> is the most frequent cause of "typical" bacterial pneumonia in children of all ages [<a href="#rid1">1,2</a>]. However, in otherwise healthy children five years and older with CAP who are not ill enough to require hospitalization, <em>M. pneumoniae</em> and <em>C. pneumoniae</em> are the most likely pathogens [<a href="#rid4">4,12,29</a>].</p><p>For children ≥5 years with clinical features strongly suggestive of typical bacterial or <em>S. pneumoniae</em> pneumonia (<a class="graphic graphic_table graphicRef52021" href="/z/d/graphic/52021.html" rel="external">table 3</a>), <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> is the drug of choice (<a class="graphic graphic_table graphicRef80561" href="/z/d/graphic/80561.html" rel="external">table 2</a>) [<a href="#rid1">1</a>]. (See <a class="local">'Suspected bacterial etiology'</a> above.)</p><p>We suggest macrolide antibiotics for initial empiric therapy for suspected atypical CAP (<a class="graphic graphic_table graphicRef52021" href="/z/d/graphic/52021.html" rel="external">table 3</a>) in children older than five years who are treated as outpatients (<a class="graphic graphic_table graphicRef80561" href="/z/d/graphic/80561.html" rel="external">table 2</a>). Macrolide antibiotics provide coverage for atypical pathogens and some coverage for <em>S. pneumoniae, </em>although macrolide resistance exists among both <em>M. pneumoniae</em> and <em>S. pneumoniae</em>.</p><p>The prevalence of macrolide-resistant <em>M. pneumoniae</em> is increasing in some geographic regions, including Asia, Europe, Israel, and the United States [<a href="#rid30">30-38</a>]. The reported prevalence of resistance among <em>M. pneumoniae</em> isolates ranges from approximately 10 percent in the United States to 90 percent in China and some parts of Japan [<a href="#rid32">32,35,39-41</a>]. Alternative agents include <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">levofloxacin</a> and <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">doxycycline</a> [<a href="#rid1">1</a>]. The long-held concern for enamel staining associated with doxycycline in children younger than eight years use is unfounded [<a href="#rid42">42,43</a>].</p><p>Among the macrolide antibiotics, <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">clarithromycin</a> and <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">azithromycin</a> have a more convenient dosing schedule and fewer side effects than <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">erythromycin</a>, but erythromycin is less expensive [<a href="#rid9">9,44,45</a>]. Macrolide antibiotics may provide coverage for <em>S. pneumoniae</em>, which is the most frequent typical bacterial pathogen for all age groups [<a href="#rid46">46-48</a>]. However, approximately 40 to 50 percent of <em>S. pneumoniae</em> isolates are resistant to macrolides. Failure to respond to macrolide therapy may indicate the development of a complication, a macrolide-resistant pathogen, and/or the need to alter therapy to provide better pneumococcal coverage. (See <a class="local">'Treatment failure'</a> below.)</p><p>Given the significant resistance of <em>S. pneumoniae</em> to macrolides, fluoroquinolones (eg, <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">levofloxacin</a>, <a class="drug drug_pediatric" data-topicid="114796" href="/z/d/drug information/114796.html" rel="external">moxifloxacin</a>) are another reasonable alternative for the outpatient treatment of CAP in the older child when typical pneumonia is also a consideration based on clinical findings (<a class="graphic graphic_table graphicRef52021" href="/z/d/graphic/52021.html" rel="external">table 3</a>). In addition to their excellent gram-negative spectrum, the fluoroquinolones are active against a number of the pathogens responsible for CAP, including beta-lactam-susceptible and nonsusceptible <em>S. pneumoniae</em>, <em>M. pneumoniae</em>, and <em>C. pneumoniae</em> [<a href="#rid49">49</a>]. However, <em>S. pneumoniae</em> resistant to levofloxacin have been identified [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H289597"><span class="h3">Suspected influenza</span><span class="headingEndMark"> — </span>Initiation of antiviral treatment for influenza (eg, <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">oseltamivir</a>) as soon as possible is recommended for children with suspected influenza who are at high risk for complications of influenza pneumonia (<a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">table 4</a>); laboratory confirmation should not delay initiation of antiviral therapy. The diagnosis and treatment of influenza in children are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">"Seasonal influenza in children: Management", section on 'Antiviral therapy'</a>.)</p><p class="headingAnchor" id="H991522735"><span class="h3">Suspected SARS-CoV-2</span><span class="headingEndMark"> — </span>SARS-CoV-2 pneumonia may be suspected in children with known exposure or circulation in the local community, school, or site of child care. The management of SARS-CoV-2 in children is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/128389.html" rel="external">"COVID-19: Management in children"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Suspected aspiration pneumonia</span><span class="headingEndMark"> — </span>Community-acquired aspiration pneumonia is usually treated with <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a>. <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">Clindamycin</a> is an alternative for patients with IgE-mediated or serious delayed reaction to a penicillin (<a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">table 6</a>). Doses are provided in the table (<a class="graphic graphic_table graphicRef80561" href="/z/d/graphic/80561.html" rel="external">table 2</a>). In neurologically compromised adolescents who may be prone to aspiration events, empiric treatment with <a class="drug drug_pediatric" data-topicid="114796" href="/z/d/drug information/114796.html" rel="external">moxifloxacin</a> (400 mg once per day) is an alternative. Moxifloxacin is active against anaerobic bacteria, as well as the usual treatable causes of CAP: <em>S. pneumoniae</em>, <em>M. pneumoniae</em>, and <em>C. pneumoniae</em>. Fluoroquinolone antibiotics generally are not recommended for children younger than 18 years of age when there is a safe and effective alternative. (See  <a class="medical medical_review" href="/z/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Children'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Duration</span><span class="headingEndMark"> — </span>The duration of therapy for children with CAP in resource-abundant countries generally is based upon the age of the host, likely causative agent, and severity of disease:</p><p class="bulletIndent1"><span class="glyph">●</span>For infants ≥4 months and children with uncomplicated pneumonia suspected or confirmed to be caused by routine bacterial pathogens (ie, <em>S. pneumoniae</em>, <em>M. pneumoniae</em>, <em>C. pneumoniae</em>), the usual suggested duration of antimicrobial therapy with agents other than <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">azithromycin</a> is seven days. For children with mild disease (<a class="graphic graphic_table graphicRef72015" href="/z/d/graphic/72015.html" rel="external">table 1</a>) and adequate follow-up, five days may be sufficient provided that the child has been afebrile for 24 hours and shows clinical improvement. The course of azithromycin is five days [<a href="#rid1">1,9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The duration of treatment for <em>C. trachomatis </em>pneumonia in young infants (&lt;4 months) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4993.html" rel="external">"Chlamydia trachomatis infections in the newborn", section on 'Treatment'</a>.)</p><p></p><p>Limited evidence from randomized trials in resource-abundant countries supports a five-day course for outpatient treatment of nonsevere CAP in select children [<a href="#rid17">17,51-55</a>]. In a meta-analysis of randomized trials evaluating short (3 to 5 days) and longer (7 to 10 days) antimicrobial therapy for uncomplicated CAP treated in the outpatient setting in resource-abundant countries [<a href="#rid17">17,51-53</a>], the rates of retreatment (approximately 8 percent; three trials, 1288 participants), hospitalization (0 percent; two trials, 478 participants), and the composite outcome of retreatment or hospitalization within one month of randomization (approximately 8 percent; four trials, 1541 participants) were similar between groups, as were rates of adverse events (approximately 62 percent; two trials, 1194 participants) [<a href="#rid54">54</a>]. Adverse events were typically mild (eg, diarrhea, rash). Trials focusing on treatment of atypical pneumonias were excluded. The mean age of the children in the trials ranged from 28 to 36.8 months. In three trials, <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> was the only antibiotic used; in the fourth trial, children were treated with amoxicillin, <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a>, or <a class="drug drug_pediatric" data-topicid="13125" href="/z/d/drug information/13125.html" rel="external">cefdinir</a>.</p><p>Although these results suggest that three to five days of antimicrobial therapy may be sufficient for the outpatient treatment of uncomplicated CAP in resource-abundant settings, we continue to treat for at least five days. The mean age of study participants was &lt;37 months, an age group in which viral pathogens predominate. Respiratory viruses were detected in &gt;80 percent of participants in the only trial that tested for them [<a href="#rid51">51</a>]. The results of the meta-analysis cannot be generalized to older children who are more likely to have bacterial pathogens.</p><p>Evidence from randomized trials that supports ≤5 days of antibiotic therapy for outpatient treatment of pneumonia in resource-limited settings cannot be generalized to resource-abundant settings [<a href="#rid56">56-58</a>]. In resource-limited settings, pneumonia is typically diagnosed according to World Health Organization criteria using respiratory rate thresholds and clinical findings [<a href="#rid59">59</a>]; many cases may be caused by viral pathogens.</p><p class="headingAnchor" id="H12"><span class="h2">Monitoring response</span><span class="headingEndMark"> — </span>Children with CAP who are treated as outpatients (including those who were not initially treated with antibiotics) should have follow-up within 24 to 48 hours [<a href="#rid1">1,2</a>]. Follow-up may be performed by phone. Children with CAP who are appropriately treated generally show signs of improvement within 48 to 72 hours.</p><p class="headingAnchor" id="H13"><span class="h3">Treatment failure</span><span class="headingEndMark"> — </span>Among patients who do not improve as anticipated, the following possibilities must be considered [<a href="#rid1">1,2,15,60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Alternative or coincident diagnoses (eg, foreign body aspiration) (see  <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Differential diagnosis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Development of complications (see  <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Complications'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ineffective antibiotic coverage (lack of coverage for the actual etiology or resistant organism)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Underlying immunodeficiency condition</p><p></p><p>The history should be reviewed with special attention to the possibility of foreign body aspiration and geographic or environmental exposures associated with pathogens not treated by the empiric regimen (<a class="graphic graphic_table graphicRef52510" href="/z/d/graphic/52510.html" rel="external">table 7</a>).</p><p class="headingAnchor" id="H264608675"><span class="h4">Worsened condition</span><span class="headingEndMark"> — </span>Patients whose condition has worsened require additional evaluation and hospitalization. They also should undergo radiologic evaluation to look for the development of complications. Laboratory tests should be performed to try to establish a microbiologic diagnosis. (See  <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Laboratory evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">"Pneumonia in children: Inpatient treatment", section on 'Hospitalization'</a>.)</p><p class="headingAnchor" id="H264608611"><span class="h4">Failure to improve</span><span class="headingEndMark"> — </span>In patients who fail to improve but have not worsened, it may be reasonable to add or strengthen coverage for <em>S. pneumoniae</em> or atypical bacteria if these organisms were not covered in the initial therapy (<a class="graphic graphic_table graphicRef80561" href="/z/d/graphic/80561.html" rel="external">table 2</a>) [<a href="#rid1">1,4</a>]. It is also important to consider underlying or comorbid conditions (eg, immunodeficiency, anatomic abnormality). (See  <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients initially treated with beta-lactam antibiotics</strong> – Failure to improve while being treated with a beta-lactam antibiotic (<a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> or cephalosporin) may indicate infection caused by penicillin-resistant <em>S. pneumoniae</em> or <em>S. aureus</em> (either methicillin-susceptible or -resistant) [<a href="#rid61">61</a>]. If penicillin-resistant <em>S. pneumoniae</em> is suspected, a change in antibiotic therapy to <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> or <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">linezolid</a> may be indicated. <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">Levofloxacin</a> is an option if there is a high rate of pneumococcal resistance to clindamycin. Doses are provided in the table (<a class="graphic graphic_table graphicRef80561" href="/z/d/graphic/80561.html" rel="external">table 2</a>). If <em>S. aureus</em> is suspected based upon a rapidly worsening clinical course with progressive radiographic findings that may include multiple patchy alveolar infiltrates coalescing to form large consolidated areas in a young, immunocompetent host often with a preceding viral illness, the child should be hospitalized given the increased risk of complications (eg, necrosis, abscess, empyema, pneumatocele) and death. (See  <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">"Pneumonia in children: Inpatient treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients initially treated with macrolide antibiotics</strong> – Failure to improve while being treated with a macrolide antibiotic may indicate the need to perform a diagnostic test (eg, polymerase chain reaction) to confirm an <em>M. pneumoniae </em>etiologic diagnosis and/or alter therapy to provide better coverage for <em>S. pneumoniae</em> or macrolide-resistant <em>M. pneumoniae</em>. (See  <a class="medical medical_review" href="/z/d/html/6070.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in children", section on 'Pneumonia'</a>.)</p><p></p><p class="bulletIndent1">For patients initially treated with macrolides, better pneumococcal coverage can be achieved by the addition of high-dose <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a>, a cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13125" href="/z/d/drug information/13125.html" rel="external">cefdinir</a>, <a class="drug drug_pediatric" data-topicid="13132" href="/z/d/drug information/13132.html" rel="external">cefpodoxime</a>), a fluoroquinolone (eg, <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">levofloxacin</a>, <a class="drug drug_pediatric" data-topicid="114796" href="/z/d/drug information/114796.html" rel="external">moxifloxacin</a>), <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">linezolid</a>, or <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> (the latter two also provide coverage for most <em>S. aureus</em> infections). Among these options, we prefer high-dose amoxicillin because it is well tolerated and inexpensive. Amoxicillin, cephalosporins, and fluoroquinolones may provide coverage for other potential, albeit less common causes, of bacterial pneumonia in older children (eg, <em>H. influenzae </em>type b, nontypeable<em> H. influenzae</em>, <em>M. catarrhalis</em>, group A <em>Streptococcus</em>) [<a href="#rid12">12</a>], although amoxicillin does not provide coverage against beta-lactamase-producing strains of <em>H. influenzae</em> and <em>M. catarrhalis.</em> For children who have an IgE-mediated or serious delayed reaction (<a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">table 6</a>) to penicillins, clindamycin, linezolid, or a fluoroquinolone (eg, levofloxacin, moxifloxacin) may be used. <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">Doxycycline</a> or fluoroquinolones can be used if macrolide-resistant <em>M. pneumoniae</em> is suspected [<a href="#rid62">62</a>]. Fluoroquinolones also provide coverage for most typical bacterial etiologies of CAP except <em>S aureus. </em>Doses are provided in the table (<a class="graphic graphic_table graphicRef80561" href="/z/d/graphic/80561.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/6070.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in children", section on 'Management'</a>.)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUPPORTIVE CARE</span><span class="headingEndMark"> — </span>The caregivers of children who are managed as outpatients should be instructed regarding management of fever and pain, maintaining adequate hydration, and identification of deterioration (eg, persistent fever, increased retractions, use of accessory muscles, grunting, inability to feed) [<a href="#rid2">2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Children with pneumonia usually have fever and may have pleuritic chest pain, which can lead to shallow breathing and impaired ability to cough [<a href="#rid2">2</a>]. Administration of antipyretics and/or analgesics can be used to keep the child comfortable. Adequate pain control may promote coughing, which facilitates airway clearance. Antitussives should be avoided as none have been found to be effective in pneumonia [<a href="#rid63">63</a>]. Symptomatic treatment of cough is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16629.html" rel="external">"The common cold in children: Management and prevention", section on 'Cough'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants and young children with respiratory distress may be better able to maintain hydration if fluids are provided in small volumes more frequently than in large volumes less often.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gentle suction of the nares may be helpful in infants and children whose nares are blocked by nasal secretions.</p><p></p><p class="headingAnchor" id="H15"><span class="h1">FOLLOW-UP</span></p><p class="headingAnchor" id="H16"><span class="h2">Clinical course</span><span class="headingEndMark"> — </span>Children who are appropriately treated for CAP gradually improve with time [<a href="#rid64">64</a>]. The symptoms associated with viral lower respiratory tract infections, particularly cough, usually resolve in less than one month in healthy infants and children but may rarely last for up to three to four months. Cough may also persist for as long as three to four months after pertussis. Children who are recovering from typical or atypical bacterial pneumonia may continue to cough for several weeks and have moderate dyspnea on exertion for two to three months [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Radiographs</span><span class="headingEndMark"> — </span>Follow-up radiographs are not necessary in asymptomatic children with uncomplicated CAP, including round pneumonia (ie, pulmonary consolidation that appears to be spherical) [<a href="#rid65">65</a>]. Follow-up radiographs two to three weeks after completion of therapy may be helpful in assessing alternate diagnoses or coincident conditions in children with recurrent pneumonia, persistent symptoms, severe atelectasis, or unusually located infiltrates [<a href="#rid1">1,2,66</a>]. Other conditions that should be considered if a round pneumonia fails to resolve on follow-up imaging, if obtained, include congenital lung sequestration, pulmonary arteriovenous malformation, metastatic Wilms tumor, cavitary necrosis, pleural pseudocyst, and primary lung carcinoma [<a href="#rid65">65-70</a>]. (See  <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Differential diagnosis'</a>.)</p><p>Several studies have evaluated the utility of follow-up radiographs in cohorts of children with acute radiologically proven CAP [<a href="#rid71">71-76</a>]. Three of the studies included clinical as well as radiologic follow-up at three to seven weeks after initial diagnosis [<a href="#rid71">71-74</a>]. In each of these studies, follow-up radiographs were normal or improved in asymptomatic children. Residual findings, even when present, did not result in additional therapy.</p><p class="headingAnchor" id="H18"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Most otherwise healthy children who develop pneumonia recover without any long-term sequelae [<a href="#rid48">48</a>]. Although some prospective studies suggest that pneumonia in childhood is associated with subsequent symptoms of asthma that may persist into adulthood, it is not clear whether this is related to unrecognized asthma at the time of presentation with pneumonia or a tendency to develop asthma after CAP [<a href="#rid77">77,78</a>].</p><p class="headingAnchor" id="H4189925122"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110776.html" rel="external">"Society guideline links: Pediatric pneumonia"</a>.)</p><p class="headingAnchor" id="H8577777"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/17120.html" rel="external">"Patient education: Pneumonia in children (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Community-acquired pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community. The clinical manifestations and diagnosis of CAP are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for hospitalization</strong> – The decision to hospitalize a child with pneumonia must be individualized and is based upon age, underlying medical problems, and severity of illness (<a class="graphic graphic_table graphicRef72015" href="/z/d/graphic/72015.html" rel="external">table 1</a>). (See <a class="local">'Indications for hospitalization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric antimicrobial therapy</strong> – Children with CAP who are treated in the outpatient setting are treated empirically. It is not necessary to obtain laboratory or radiographic data in an attempt to suggest a bacterial etiology in children who are well enough to be treated as outpatients. Decisions regarding empiric antimicrobial therapy for CAP in children are usually based upon age unless there are other overriding epidemiologic or clinical factors to suggest a specific etiologic agent. (See <a class="local">'Factors influencing choice of regimen'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age &lt;6 months – Infants younger than three to six months of age with suspected bacterial CAP or who are hypoxemic should be admitted to the hospital for management.</p><p></p><p class="bulletIndent2">Afebrile infants one to four months of age who are thought to have afebrile pneumonia of infancy (e<em>g, Chlamydia trachomatis</em>) can be treated in the outpatient setting if they are not hypoxemic and remain afebrile. (See  <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">"Pneumonia in children: Inpatient treatment"</a> and  <a class="medical medical_review" href="/z/d/html/4993.html" rel="external">"Chlamydia trachomatis infections in the newborn"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age 6 months to 5 years – We recommend that empiric antibiotic therapy for CAP in children six months to five years of age who are thought to have bacterial pneumonia (eg, abrupt onset, moderate to severe respiratory distress, and supportive laboratory data if obtained (<a class="graphic graphic_table graphicRef52021" href="/z/d/graphic/52021.html" rel="external">table 3</a>)) include coverage for <em>Streptococcus pneumoniae </em>(<a class="graphic graphic_table graphicRef80561" href="/z/d/graphic/80561.html" rel="external">table 2</a>) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). We prefer high-dose <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> for <em>S. pneumoniae</em> coverage. (See <a class="local">'Children &lt;5 years'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age ≥5 years</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Suspected typical bacterial pneumonia – For children ≥5 years with clinical features strongly suggestive of typical bacterial (eg, <em>S. pneumoniae</em>) pneumonia (<a class="graphic graphic_table graphicRef52021" href="/z/d/graphic/52021.html" rel="external">table 3</a>), <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> is the drug of choice (<a class="graphic graphic_table graphicRef80561" href="/z/d/graphic/80561.html" rel="external">table 2</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Suspected atypical bacterial pneumonia – We initiate a macrolide antibiotic for initial empiric therapy for suspected atypical CAP (<a class="graphic graphic_table graphicRef52021" href="/z/d/graphic/52021.html" rel="external">table 3</a>) in children ≥5 years who are treated as outpatients. (See <a class="local">'Children ≥5 years'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of antimicrobial therapy</strong> – In infants and children four months and older with uncomplicated pneumonia, the usual duration of antimicrobial therapy is seven days for agents other than <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">azithromycin</a>; for children with mild disease and adequate follow-up, five days may be sufficient, provided that the child has been afebrile for 24 hours and shows clinical improvement. The course of azithromycin is five days. (See <a class="local">'Duration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up and clinical course</strong> – Children who are treated for CAP as outpatients should have follow-up within 24 to 48 hours. Those whose condition has worsened at follow-up should be evaluated for potential complications and hospitalized. (See <a class="local">'Monitoring response'</a> above and  <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">"Pneumonia in children: Inpatient treatment"</a>.)</p><p></p><p class="bulletIndent1">Children recovering from CAP may continue to cough for several weeks to four months, depending upon the etiology. Those recovering from typical or atypical bacterial pneumonia may have moderate dyspnea on exertion for two to three months. (See <a class="local">'Clinical course'</a> above.)</p><p></p><p class="bulletIndent1">Follow-up radiographs in children with uncomplicated CAP who remain asymptomatic are not needed. Follow-up radiographs two to three weeks after completion of therapy may be helpful in children with recurrent pneumonia, persistent symptoms, severe atelectasis, or unusually located infiltrates. (See <a class="local">'Radiographs'</a> above.)</p><p></p><p class="bulletIndent1">Most otherwise healthy children who develop pneumonia recover without any long-term sequelae. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.</a></li><li><a class="nounderline abstract_t">Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66 Suppl 2:ii1.</a></li><li><a class="nounderline abstract_t">Russell G. Community acquired pneumonia. Arch Dis Child 2001; 85:445.</a></li><li><a class="nounderline abstract_t">McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429.</a></li><li><a class="nounderline abstract_t">Esposito S, Bosis S, Cavagna R, et al. Characteristics of Streptococcus pneumoniae and atypical bacterial infections in children 2-5 years of age with community-acquired pneumonia. Clin Infect Dis 2002; 35:1345.</a></li><li><a class="nounderline abstract_t">Virkki R, Juven T, Rikalainen H, et al. Differentiation of bacterial and viral pneumonia in children. Thorax 2002; 57:438.</a></li><li><a class="nounderline abstract_t">Aliberti S, Dela Cruz CS, Amati F, et al. Community-acquired pneumonia. Lancet 2021; 398:906.</a></li><li><a class="nounderline abstract_t">Low DE, Pichichero ME, Schaad UB. Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance. Clin Pediatr (Phila) 2004; 43:135.</a></li><li><a class="nounderline abstract_t">Harris JA, Kolokathis A, Campbell M, et al. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J 1998; 17:865.</a></li><li><a class="nounderline abstract_t">Wubbel L, Muniz L, Ahmed A, et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr Infect Dis J 1999; 18:98.</a></li><li><a class="nounderline abstract_t">Ambroggio L, Test M, Metlay JP, et al. Comparative Effectiveness of Beta-lactam Versus Macrolide Monotherapy in Children with Pneumonia Diagnosed in the Outpatient Setting. Pediatr Infect Dis J 2015; 34:839.</a></li><li><a class="nounderline abstract_t">Jadavji T, Law B, Lebel MH, et al. A practical guide for the diagnosis and treatment of pediatric pneumonia. CMAJ 1997; 156:S703.</a></li><li><a class="nounderline abstract_t">Tapiainen T, Aittoniemi J, Immonen J, et al. Finnish guidelines for the treatment of community-acquired pneumonia and pertussis in children. Acta Paediatr 2016; 105:39.</a></li><li><a class="nounderline abstract_t">Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003; 46:285.</a></li><li><a class="nounderline abstract_t">Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286:1857.</a></li><li><a class="nounderline abstract_t">Kaur R, Pham M, Yu KOA, Pichichero ME. Rising Pneumococcal Antibiotic Resistance in the Post-13-Valent Pneumococcal Conjugate Vaccine Era in Pediatric Isolates From a Primary Care Setting. Clin Infect Dis 2021; 72:797.</a></li><li><a class="nounderline abstract_t">Bielicki JA, Stöhr W, Barratt S, et al. Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial. JAMA 2021; 326:1713.</a></li><li><a class="nounderline abstract_t">Olarte L, Barson WJ, Barson RM, et al. Pneumococcal Pneumonia Requiring Hospitalization in US Children in the 13-Valent Pneumococcal Conjugate Vaccine Era. Clin Infect Dis 2017; 64:1699.</a></li><li class="breakAll">International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health. Gap analysis of PCV impact evaluations in settings of routine use. February 2017. Available at: https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html (Accessed on March 16, 2018).</li><li><a class="nounderline abstract_t">Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:109.</a></li><li><a class="nounderline abstract_t">Hoberman A, Paradise JL, Burch DJ, et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Pediatr Infect Dis J 1997; 16:463.</a></li><li><a class="nounderline abstract_t">Behre U, Burow HM, Quinn P, et al. Efficacy of twice-daily dosing of amoxycillin/clavulanate in acute otitis media in children. Infection 1997; 25:163.</a></li><li><a class="nounderline abstract_t">Principi N, Marchisio P, Bigalli L, Massironi E. Amoxicillin twice daily in the treatment of acute otitis media in infants and children. Eur J Pediatr 1986; 145:522.</a></li><li><a class="nounderline abstract_t">Bradley JS, Garonzik SM, Forrest A, Bhavnani SM. Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infection. Pediatr Infect Dis J 2010; 29:1043.</a></li><li><a class="nounderline abstract_t">Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and Management of Penicillin Allergy: A Review. JAMA 2019; 321:188.</a></li><li><a class="nounderline abstract_t">Vyles D, Chiu A, Routes J, et al. Oral amoxicillin challenges in low-risk children during a pediatric emergency department visit. J Allergy Clin Immunol Pract 2020; 8:1126.</a></li><li><a class="nounderline abstract_t">Baskin MN, O'Rourke EJ, Fleisher GR. Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone. J Pediatr 1992; 120:22.</a></li><li><a class="nounderline abstract_t">Chumpa A, Bachur RG, Harper MB. Bacteremia-associated pneumococcal pneumonia and the benefit of initial parenteral antimicrobial therapy. Pediatr Infect Dis J 1999; 18:1081.</a></li><li><a class="nounderline abstract_t">Hammerschlag MR. Atypical pneumonias in children. Adv Pediatr Infect Dis 1995; 10:1.</a></li><li><a class="nounderline abstract_t">Peuchant O, Ménard A, Renaudin H, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009; 64:52.</a></li><li><a class="nounderline abstract_t">Averbuch D, Hidalgo-Grass C, Moses AE, et al. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis 2011; 17:1079.</a></li><li><a class="nounderline abstract_t">Yamada M, Buller R, Bledsoe S, Storch GA. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis J 2012; 31:409.</a></li><li><a class="nounderline abstract_t">Kawai Y, Miyashita N, Yamaguchi T, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology 2012; 17:354.</a></li><li><a class="nounderline abstract_t">Chironna M, Sallustio A, Esposito S, et al. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother 2011; 66:734.</a></li><li><a class="nounderline abstract_t">Liu Y, Ye X, Zhang H, et al. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn Microbiol Infect Dis 2010; 67:355.</a></li><li><a class="nounderline abstract_t">Miyashita N, Kawai Y, Akaike H, et al. Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia. BMC Infect Dis 2012; 12:126.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Mycoplasma pneumoniae respiratory illness - two rural counties, West Virginia, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:834.</a></li><li><a class="nounderline abstract_t">Wu PS, Chang LY, Lin HC, et al. Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Taiwan. Pediatr Pulmonol 2013; 48:904.</a></li><li><a class="nounderline abstract_t">Kawai Y, Miyashita N, Kubo M, et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents Chemother 2013; 57:4046.</a></li><li><a class="nounderline abstract_t">Zheng X, Lee S, Selvarangan R, et al. Macrolide-Resistant Mycoplasma pneumoniae, United States. Emerg Infect Dis 2015; 21:1470.</a></li><li><a class="nounderline abstract_t">Kim K, Jung S, Kim M, et al. Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis. JAMA Netw Open 2022; 5:e2220949.</a></li><li><a class="nounderline abstract_t">Todd SR, Dahlgren FS, Traeger MS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever. J Pediatr 2015; 166:1246.</a></li><li><a class="nounderline abstract_t">Pöyhönen H, Nurmi M, Peltola V, et al. Dental staining after doxycycline use in children. J Antimicrob Chemother 2017; 72:2887.</a></li><li><a class="nounderline abstract_t">Block S, Hedrick J, Hammerschlag MR, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 1995; 14:471.</a></li><li><a class="nounderline abstract_t">Chien SM, Pichotta P, Siepman N, Chan CK. Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group. Chest 1993; 103:697.</a></li><li><a class="nounderline abstract_t">Pelton SI, Hammerschlag MR. Overcoming current obstacles in the management of bacterial community-acquired pneumonia in ambulatory children. Clin Pediatr (Phila) 2005; 44:1.</a></li><li><a class="nounderline abstract_t">Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333:1618.</a></li><li><a class="nounderline abstract_t">Sandora TJ, Harper MB. Pneumonia in hospitalized children. Pediatr Clin North Am 2005; 52:1059.</a></li><li><a class="nounderline abstract_t">Bradley JS, Arguedas A, Blumer JL, et al. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J 2007; 26:868.</a></li><li><a class="nounderline abstract_t">Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:747.</a></li><li><a class="nounderline abstract_t">Pernica JM, Harman S, Kam AJ, et al. Short-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trial. JAMA Pediatr 2021; 175:475.</a></li><li><a class="nounderline abstract_t">Greenberg D, Givon-Lavi N, Sadaka Y, et al. Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children: a double-blind, randomized, placebo-controlled trial. Pediatr Infect Dis J 2014; 33:136.</a></li><li><a class="nounderline abstract_t">Williams DJ, Creech CB, Walter EB, et al. Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial. JAMA Pediatr 2022; 176:253.</a></li><li><a class="nounderline abstract_t">Kuitunen I, Jääskeläinen J, Korppi M, Renko M. Antibiotic Treatment Duration for Community-Acquired Pneumonia in Outpatient Children in High-Income Countries-A Systematic Review and Meta-Analysis. Clin Infect Dis 2023; 76:e1123.</a></li><li><a class="nounderline abstract_t">Li Q, Zhou Q, Florez ID, et al. Short-Course vs Long-Course Antibiotic Therapy for Children With Nonsevere Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. JAMA Pediatr 2022; 176:1199.</a></li><li><a class="nounderline abstract_t">Haider BA, Saeed MA, Bhutta ZA. Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59 months. Cochrane Database Syst Rev 2008; :CD005976.</a></li><li><a class="nounderline abstract_t">Ginsburg AS, Mvalo T, Nkwopara E, et al. Amoxicillin for 3 or 5 Days for Chest-Indrawing Pneumonia in Malawian Children. N Engl J Med 2020; 383:13.</a></li><li><a class="nounderline abstract_t">Chang AB, Grimwood K. Antibiotics for Childhood Pneumonia - Do We Really Know How Long to Treat? N Engl J Med 2020; 383:77.</a></li><li class="breakAll">World Health Organization. Revised WHO classification and treatment of childhood pneumonia at health facilities (2014). https://www.who.int/news-room/fact-sheets/detail/pneumonia (Accessed on March 23, 2021).</li><li><a class="nounderline abstract_t">Alves dos Santos JW, Torres A, Michel GT, et al. Non-infectious and unusual infectious mimics of community-acquired pneumonia. Respir Med 2004; 98:488.</a></li><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Bébéar C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol 2011; 6:423.</a></li><li><a class="nounderline abstract_t">Chang CC, Cheng AC, Chang AB. Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Database Syst Rev 2014; :CD006088.</a></li><li><a class="nounderline abstract_t">Gaston B. Pneumonia. Pediatr Rev 2002; 23:132.</a></li><li><a class="nounderline abstract_t">McCrossan P, McNaughten B, Shields M, Thompson A. Is follow up chest X-ray required in children with round pneumonia? Arch Dis Child 2017; 102:1182.</a></li><li><a class="nounderline abstract_t">Griscom NT. Pneumonia in children and some of its variants. Radiology 1988; 167:297.</a></li><li><a class="nounderline abstract_t">McLennan MK. Radiology rounds. Round pneumonia. Can Fam Physician 1998; 44:751, 757.</a></li><li><a class="nounderline abstract_t">Kim YW, Donnelly LF. Round pneumonia: imaging findings in a large series of children. Pediatr Radiol 2007; 37:1235.</a></li><li><a class="nounderline abstract_t">Eggli KD, Newman B. Nodules, masses, and pseudomasses in the pediatric lung. Radiol Clin North Am 1993; 31:651.</a></li><li><a class="nounderline abstract_t">Rose RW, Ward BH. Spherical pneumonias in children simulating pulmonary and mediastinal masses. Radiology 1973; 106:179.</a></li><li><a class="nounderline abstract_t">Grossman LK, Wald ER, Nair P, Papiez J. Roentgenographic follow-up of acute pneumonia in children. Pediatrics 1979; 63:30.</a></li><li><a class="nounderline abstract_t">Virkki R, Juven T, Mertsola J, Ruuskanen O. Radiographic follow-up of pneumonia in children. Pediatr Pulmonol 2005; 40:223.</a></li><li><a class="nounderline abstract_t">Gibson NA, Hollman AS, Paton JY. Value of radiological follow up of childhood pneumonia. BMJ 1993; 307:1117.</a></li><li><a class="nounderline abstract_t">Heaton P, Arthur K. The utility of chest radiography in the follow-up of pneumonia. N Z Med J 1998; 111:315.</a></li><li><a class="nounderline abstract_t">Wacogne I, Negrine RJ. Are follow up chest x ray examinations helpful in the management of children recovering from pneumonia? Arch Dis Child 2003; 88:457.</a></li><li><a class="nounderline abstract_t">Surén P, Try K, Eriksson J, et al. Radiographic follow-up of community-acquired pneumonia in children. Acta Paediatr 2008; 97:46.</a></li><li><a class="nounderline abstract_t">Clark CE, Coote JM, Silver DA, Halpin DM. Asthma after childhood pneumonia: six year follow up study. BMJ 2000; 320:1514.</a></li><li><a class="nounderline abstract_t">Chan JY, Stern DA, Guerra S, et al. Pneumonia in childhood and impaired lung function in adults: a longitudinal study. Pediatrics 2015; 135:607.</a></li></ol></div><div id="topicVersionRevision">Topic 5987 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880587" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21903691" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11719321" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Community acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11832532" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Community-acquired pneumonia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12439797" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Characteristics of Streptococcus pneumoniae and atypical bacterial infections in children 2-5 years of age with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11978922" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Differentiation of bacterial and viral pneumonia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34481570" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15024437" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9802626" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10048679" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Etiology and treatment of community-acquired pneumonia in ambulatory children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25955834" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Comparative Effectiveness of Beta-lactam Versus Macrolide Monotherapy in Children with Pneumonia Diagnosed in the Outpatient Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9068582" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A practical guide for the diagnosis and treatment of pediatric pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26341383" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Finnish guidelines for the treatment of community-acquired pneumonia and pertussis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12944021" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11597287" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Macrolide resistance among invasive Streptococcus pneumoniae isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32067037" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Rising Pneumococcal Antibiotic Resistance in the Post-13-Valent Pneumococcal Conjugate Vaccine Era in Pediatric Isolates From a Primary Care Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34726708" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28199482" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pneumococcal Pneumonia Requiring Hospitalization in US Children in the 13-Valent Pneumococcal Conjugate Vaccine Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28199482" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pneumococcal Pneumonia Requiring Hospitalization in US Children in the 13-Valent Pneumococcal Conjugate Vaccine Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35085226" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9154538" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9181384" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy of twice-daily dosing of amoxycillin/clavulanate in acute otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3545844" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Amoxicillin twice daily in the treatment of acute otitis media in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20975453" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30644987" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Evaluation and Management of Penicillin Allergy: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31586667" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Oral amoxicillin challenges in low-risk children during a pediatric emergency department visit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1731019" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10608629" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Bacteremia-associated pneumococcal pneumonia and the benefit of initial parenteral antimicrobial therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7718203" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Atypical pneumonias in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19429926" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21749775" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22209916" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22077195" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21393214" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20638604" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22650321" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23076092" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mycoplasma pneumoniae respiratory illness - two rural counties, West Virginia, 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23169584" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23716043" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26196107" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Macrolide-Resistant Mycoplasma pneumoniae, United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35816304" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25794784" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29091225" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Dental staining after doxycycline use in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7667050" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8449054" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15678226" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Overcoming current obstacles in the management of bacterial community-acquired pneumonia in ambulatory children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7477199" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009257" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pneumonia in hospitalized children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901791" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11882730" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33683325" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Short-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23989106" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children: a double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35040920" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35579504" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Antibiotic Treatment Duration for Community-Acquired Pneumonia in Outpatient Children in High-Income Countries-A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36374480" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Short-Course vs Long-Course Antibiotic Therapy for Children With Nonsevere Community-Acquired Pneumonia: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18425930" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32609979" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Amoxicillin for 3 or 5 Days for Chest-Indrawing Pneumonia in Malawian Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32609987" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Antibiotics for Childhood Pneumonia - Do We Really Know How Long to Treat?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32609987" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Antibiotics for Childhood Pneumonia - Do We Really Know How Long to Treat?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15191032" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Non-infectious and unusual infectious mimics of community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21526943" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mycoplasma pneumoniae: susceptibility and resistance to antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24615334" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11927745" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29021188" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Is follow up chest X-ray required in children with round pneumonia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3357939" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pneumonia in children and some of its variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9585845" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Radiology rounds. Round pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17952428" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Round pneumonia: imaging findings in a large series of children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8497596" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Nodules, masses, and pseudomasses in the pediatric lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4682716" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Spherical pneumonias in children simulating pulmonary and mediastinal masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/440799" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Roentgenographic follow-up of acute pneumonia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16010671" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Radiographic follow-up of pneumonia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8251812" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Value of radiological follow up of childhood pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9765629" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The utility of chest radiography in the follow-up of pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12716727" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Are follow up chest x ray examinations helpful in the management of children recovering from pneumonia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18076723" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Radiographic follow-up of community-acquired pneumonia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10834897" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Asthma after childhood pneumonia: six year follow up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25733757" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pneumonia in childhood and impaired lung function in adults: a longitudinal study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
